Joint pain in patients with atopic dermatitis receiving treatment with dupilumab : A US nationwide cohort study
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 2023 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:90 |
|---|---|
| Enthalten in: |
Journal of the American Academy of Dermatology - 90(2023), 1 vom: 21. Jan., Seite 134-137 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Schneeweiss, Maria C [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
420K487FSG |
|---|
| Anmerkungen: |
Date Completed 16.12.2023 Date Revised 16.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jaad.2023.08.025 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36102827X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36102827X | ||
| 003 | DE-627 | ||
| 005 | 20231227132934.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jaad.2023.08.025 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1230.xml |
| 035 | |a (DE-627)NLM36102827X | ||
| 035 | |a (NLM)37604229 | ||
| 035 | |a (PII)S0190-9622(23)02518-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Schneeweiss, Maria C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Joint pain in patients with atopic dermatitis receiving treatment with dupilumab |b A US nationwide cohort study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.12.2023 | ||
| 500 | |a Date Revised 16.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a arthralgia | |
| 650 | 4 | |a arthritis | |
| 650 | 4 | |a atopic dermatitis | |
| 650 | 4 | |a dupilumab | |
| 650 | 4 | |a epidemiology | |
| 650 | 4 | |a immunomodulating drugs | |
| 650 | 4 | |a safety | |
| 650 | 4 | |a systemic medications | |
| 650 | 7 | |a dupilumab |2 NLM | |
| 650 | 7 | |a 420K487FSG |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 700 | 1 | |a Wyss, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Schneeweiss, Sebastian |e verfasserin |4 aut | |
| 700 | 1 | |a Anand, Priyanka |e verfasserin |4 aut | |
| 700 | 1 | |a Jin, Yinzhu |e verfasserin |4 aut | |
| 700 | 1 | |a Dicesare, Elyse |e verfasserin |4 aut | |
| 700 | 1 | |a Glynn, Robert J |e verfasserin |4 aut | |
| 700 | 1 | |a Merola, Joseph F |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the American Academy of Dermatology |d 1984 |g 90(2023), 1 vom: 21. Jan., Seite 134-137 |w (DE-627)NLM000422703 |x 1097-6787 |7 nnns |
| 773 | 1 | 8 | |g volume:90 |g year:2023 |g number:1 |g day:21 |g month:01 |g pages:134-137 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jaad.2023.08.025 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 90 |j 2023 |e 1 |b 21 |c 01 |h 134-137 | ||